References
- ZhuangSHXiuLElsayedYAOverall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacyCancer J200915539540019826359
- DriscollJJRixeOOverall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trialsCancer J200915540140519826360
- DavisSTappendenPCantrellAA Review of Studies Examining the Relationship between Progression-Free Survival and Overall Survival in Advanced or Metastatic CancerSheffieldSchool of Health and Related Research, University of Sheffield2012
- Di LeoABleibergHBuyseMOverall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancerJ Clin Oncol200321102045204712743164
- SaadEDKatzABuyseMOverall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trialsJ Clin Oncol201028111958196220194852
- US Department of Health and Human Services Food and Drug AdministrationGuidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Available from: https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdfAccessed March 19, 2017
- BuyseMBurzykowskiTCarrollKProgression-free survival is a surrogate for survival in advanced colorectal cancerJ Clin Oncol200725335218522418024867
- SridharaRJohnsonJRJusticeRKeeganPChakravartyAPazdurRReview of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007J Natl Cancer Inst2010102423024320118413
- JohnsonJRWilliamsGPazdurREnd points and United States Food and Drug Administration approval of oncology drugsJ Clin Oncol20032171404141112663734
- CortazarPJusticeRJohnsonJSridharaRKeeganPPazdurRUS Food and Drug Administration approval overview in metastatic breast cancerJ Clin Oncol201230141705171122430273
- SmithIGoals of treatment for patients with metastatic breast cancerSemin Oncol200633suppl 225
- SaadEDBuyseMStatistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agentsAnn Oncol201627337337826578738
- SwinscowTDVCampbellMJ webpage on the InternetSection 11 Correlations and regressions Statistics at Square One9th edLondonBMJ Publishing Group Ltd1997 Available from: http://www.bmj.com/about-bmj/resources-readers/publications/statistics-square-one/11-correlation-and-regressionAccessed March 19, 2017
- BurzykowskiTMGBuyseMThe Evaluation of Surrogate EndpointsNew YorkSpringer2005
- ForsytheAChandiwanaDBarthJThabaneMBaeckJTremblayGIs progression-free survival a more relevant endpoint than overall survival in first-line HR+, HER2− metastatic breast cancer?Cancer Manag Res In press2018